Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study) Meeting Abstract
| Authors: | Silbermann, R.; Laubach, J.; Kaufman, J.; Sborov, D.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L.; Anderson, L.; Nathwani, N.; Shah, N.; Bumma, N.; Costello, C.; Jakubowiak, A.; Orlowski, R.; Shain, K.; Gries, K.; Pei, H.; Cortoos, A.; Patel, S.; Matt, K.; Lin, T.; Usmani, S.; Voorhees, P.; Richardson, P. |
| Abstract Title: | Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study) |
| Meeting Title: | 20th Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Sep 27-30 |
| Meeting Location: | Athens, Greece |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S125 |
| End Page: | S126 |
| Language: | English |
| ACCESSION: | WOS:001079705400216 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01782-2 |
| Notes: | Meeting Abstract: P-164 -- Source: Wos |
